Supplementary Table S1 from Race-Related Differences in Sipuleucel-T Response among Men with Metastatic Castrate–Resistant Prostate Cancer

Heath, Elisabeth I.; Thakur, Archana; Chen, Wei; Hwang, Clara; Paller, Channing J.; Cackowski, Frank C.; Boerner, Julie L.; Heilbrun, Lance; Smith, Melanie P.; Schalk, Dana L.; Schienschang, Amy; Whitaker, Sarah A.; Polend, Amanda; Smith, Daryn; Vaishampayan, Ulka N.; Dickow, Brenda; Lum, Lawrence G.

doi:10.1158/2767-9764.26885834.v1

- No file added yet -

Supplementary Table S1 from Race-Related Differences in Sipuleucel-T Response among Men with Metastatic Castrate–Resistant Prostate Cancer

journal contribution

posted on 2024-08-31, 09:00 authored by Elisabeth I. Heath, Archana Thakur, Wei Chen, Clara Hwang, Channing J. Paller, Frank C. Cackowski, Julie L. Boerner, Lance Heilbrun, Melanie P. Smith, Dana L. Schalk, Amy Schienschang, Sarah A. Whitaker, Amanda Polend, Daryn Smith, Ulka N. Vaishampayan, Brenda Dickow, Lawrence G. Lum

Antibody and IFN-γ responses and co-stimulatory and co-inhibitory marker expressions in mCRPC patients.

History

ARTICLE ABSTRACT

Sipuleucel-T is an autologous cellular immunotherapy that targets prostatic acid phosphatase (PAP) and is available for treatment of men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). In this single-arm, two-cohort, multicenter clinical study, potential racial differences in immune responses to sipuleucel-T in men with mCRPC were explored. Patients’ blood samples were obtained to assess serum cytokines, humoral responses, and cellular immunity markers before and after treatment. Baseline cumulative product parameters (total nucleated and CD54+ cell counts and CD54 upregulation) were evaluated. IgM titers against the immunogen PA2024, the target antigen PAP, prostate-specific membrane antigen (PSMA) and prostate-specific antigen (PSA) were quantified by ELISA. Cytotoxic T-lymphocyte activity was determined by ELISpots, and cytokine and chemokine concentrations were determined by Luminex.Twenty-nine African American (AA) men and 28 non-African American (non-AA) men with mCRPC received sipuleucel-T. Baseline total nucleated cell count, CD54+ cell count, CD54 expression, and cumulative product parameters were higher in non-AA men. Although PSA baseline levels were higher in AA men, there were no racial differences in IgM antibody and IFNγ ELISpots responses against PA2024, PAP, PSA, and PSMA before and after treatment. Expression of co-stimulatory receptor ICOS on CD4+ and CD8+ T cells, and the levels of Th1 cytokine granulocyte-macrophage colony-stimulating factor and chemokines CCL4 and CCL5, were significantly higher in AA men before and/or after treatment. Despite no difference in the overall survival, PSA changes from baseline were significantly different between the two races. The data suggest that immune correlates in blood differ in AA and non-AA men with mCRPC pre- and post-sipuleucel-T. Our novel findings of higher expression of co-stimulatory receptor ICOS on CD4+ and CD8+ T cells in African American patients with metastatic castrate-resistant prostate cancer (mCRPC) prior and post-sipuleucel-T suggest activation of CD4+ and CD8+ T cells. The data indicate that racial differences observed in these and other immune correlates before and after sipuleucel-T warrant additional investigation to further our understanding of the immune system in African American men and other men with mCRPC.